Foundational Overview of HDV

CE / CME

Hepatitis Delta in Focus: A Foundational Overview of HDV

Pharmacists: 0.75 contact hour (0.075 CEUs)

Nurses: 0.75 Nursing contact hour

Physicians: Maximum of 0.75 AMA PRA Category 1 Credit

Released: December 09, 2022

Expiration: December 08, 2023

Nancy Reau
Nancy Reau, MD

Activity

Progress
1
Course Completed
LIFT-HDV: Lonafarnib, Ritonavir, and Peginterferon- λ for Chronic HDV Infection

Let us consider other agents under investigation.

The LIFT HDV study was a phase IIa study assessing use of lonafarnib, ritonavir, and peginterferon-λ for 24 weeks in patients with chronic HDV infection. Individuals received HBV treatment with a nucleoside or nucleotide analog for at least 3 months to ensure their HBV DNA was suppressed and no HBV flares occurred. In total, 26 patients were included in the study and were followed an additional 24 weeks after treatment completion.20

By the end of therapy, 77% of patients achieved a 2-log drop in HDV RNA and 50% patients had an undetectable HDV RNA.

Five patients discontinued therapy, often for treatment-related adverse events, and 2 patients required dose reductions.

The durable virologic response (ie, HDV RNA below the limit of quantification at 24 weeks post treatment) was 23% at Week 48.

More data about lonafarnib and peginterferon-λ are anticipated as further studies are underway (NCT05229991, NCT03719313, NCT05070364).